The ACHIEVE study (22) showed that high-dose aumolertinib (165 mg/day) administered as first-line treatment to patients with EGFR-positive NSCLC with BM resulted in a 12-month intracranial PFS (iPFS) rate of 75.0%, with the miPFS not reached. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.